Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Blood Advances Année : 2021

Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified

Estelle Bourbon
  • Fonction : Auteur
Juliette Fontaine
  • Fonction : Auteur
Claire Mauduit
  • Fonction : Auteur
Pierre Sesques
  • Fonction : Auteur
Violaine Safar
  • Fonction : Auteur
Emmanuelle Ferrant
  • Fonction : Auteur
Camille Golfier
  • Fonction : Auteur
Dana Ghergus
  • Fonction : Auteur
Lionel Karlin
  • Fonction : Auteur
Anne Lazareth
  • Fonction : Auteur
Fadhela Bouafia
Gian Matteo Pica
  • Fonction : Auteur
Frédérique Orsini-Piocelle
  • Fonction : Auteur
Clément Rocher
  • Fonction : Auteur
François-Xavier Gros
Marie Parrens
  • Fonction : Auteur
Arthur Dony
  • Fonction : Auteur
Cédric Rossi
Hervé Ghesquières
  • Fonction : Auteur
Emmanuel Bachy
Alexandra Traverse-Glehen
  • Fonction : Auteur
Clémentine Sarkozy
  • Fonction : Auteur

Résumé

Abstract In this retrospective study, we report 70 cases of Epstein-Barr virus (EBV)+ diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS) among 1696 DLBCL-NOS cases diagnosed between 2006 and 2019 (prevalence of 4.1%). At diagnosis, median age was 68.5 years; 79% of the cases presented with an advanced-stage disease (III-IV), 48% with extranodal lesions, and 14% with an hemophagocytic lymphohistiocytosis (HLH) (8 at diagnosis and 1 on therapy). A total of 46 cases presented a polymorphic pattern, and 21 were monomorphic. All had a non-germinal center B phenotype, with the majority of tumor cells expressing CD30 and programmed death ligand 1 (98% and 95%, respectively). Type II and III EBV latency was seen in 88% and 12% of the cases, respectively. Patients were treated with immunochemotherapy (59%) or chemotherapy (22%), and 19% received palliative care due to advanced age and altered performance status. After a median follow-up of 48 months, progression-free survival (PFS) and overall survival (OS) at 5 years were 52.7% and 54.8%, respectively. Older age (>50 years) and HLH were associated with shorter PFS and OS in multivariate analysis (PFS: hazard ratio [HR], 14.01; 95% confidence interval [CI], 2.34-83.97; and HR, 5.78; 95% CI, 2.35-14.23; OS: HR, 12.41; 95% CI, 1.65-93.53; and HR, 6.09; 95% CI, 2.42-15.30, respectively). Finally, using a control cohort of 425 EBV− DLBCL-NOS, EBV positivity was associated with a shorter OS outcome within patients >50 years (5-year OS, 53% [95% CI, 38.2-74] vs 60.8% [95% CI, 55.4-69.3], P = .038), but not in younger patients.

Dates et versions

hal-04151083 , version 1 (04-07-2023)

Identifiants

Citer

Estelle Bourbon, Delphine Maucort-Boulch, Juliette Fontaine, Claire Mauduit, Pierre Sesques, et al.. Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. Blood Advances, 2021, 5 (16), pp.3227-3239. ⟨10.1182/bloodadvances.2021004515⟩. ⟨hal-04151083⟩

Collections

HCL
3 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More